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ABSTRACT
Headache is one of the most common conditions
presenting to the neurology clinic, yet a
significant proportion of these patients are
unsatisfied by their clinic experience. Headache
can be extremely disabling; effective treatment is
not only essential for patients but is rewarding
for the physician. In this first of two parts review
of headache, we provide an overview of
headache management, emerging therapeutic
strategies and an accessible interpretation of
clinical guidelines to assist the busy neurologist.
BACKGROUND
Headache is listed among the WHO’s
major causes of disability with a global
prevalence of 47% (symptoms occurring
at least once in the past year). It is the
commonest neurological syndrome pre-
senting to primary care with 3% of adults
consulting a general practitioner for head-
ache each year.1 Women are dispropor-
tionately affected (3:1) and its higher
prevalence among those of working age
adds to the socioeconomic burden with
loss of productivity, estimated at £2.25
billion per year in the UK.2
In neurological practice, headache
accounts for 25% of new referrals and
yet a large proportion of these patients
feel dissatisfied even if they make it to
the neurology clinic, partly due to a
reported lack of interest in the disorder
by the reviewing neurologist.2 Most
patients with headache have migraine,
and when this diagnosis is made it is
usually correct (98%).3 However, a
quarter of patients with migraine have as
their diagnosis missed. Furthermore, of
those identified as a non-migrainous
primary headache, 82% actually have
migraine or probable migraine.3
Neurologists consequently see a lot of
patients with headache and the condition
is very disabling for individuals. A diagno-
sis, empathy and effective treatment make
a huge difference to the patient and can
be very rewarding for the clinician. The
purpose of this article, the first of two
linked articles, is to provide an up-to-date
overview of the pharmacological manage-
ment of common headache disorders
(as well as a limited number of non-
pharmaceutical strategies).
THE COMMON PRIMARY HEADACHE
DISORDERS
In European populations, the annual sex-
adjusted prevalence for tension-type
headache is 35%, for migraine is 38%,
but for cluster headache is only
0.15%.4 5 These three together comprise
the most prevalent primary headache dis-
orders. The remaining primary headache
diagnoses—all relatively rare—include
paroxysmal hemicrania, hemicrania con-
tinua, short-lasting unilateral neuralgi-
form headache attacks, hypnic headache
and new daily persistent headache.
Table 1 outlines the features that help to
distinguish these disorders.
Migraine is a common and disabling
primary headache disorder and is the
focus of this article. We also briefly con-
sider the other common primary head-
ache disorders, tension-type headache,
cluster headache and also the manage-
ment of medication-overuse headache.
MIGRAINE
The changing theories of migraine
The vascular hypothesis was central to
early understanding of migraine patho-
physiology. Its central premise was that
intracranial vasoconstriction caused the
aura, while reflexive secondary vasodila-
tation generated pain through perivascu-
lar nerves. However, advances in
intracerebral blood flow imaging have
largely refuted this hypothesis.
The neurovascular hypothesis posits
that migraine is a disorder of the
endogenous pain modulating systems,
particularly the subcortical structures.
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Table 1 Key clinical features that assist the differentiation of more common headache disorders
Headache Tension-type headache Migraine
Trigeminal autonomic cephalalgias
Trigeminal
neuralgiaCluster headache
Paroxysmal
hemicrania
Hemicrania
continua SUNCT/SUNA
Sex (M:F) 4:5 3:1 5:1 1:1 1:2 3:2 2:3
Duration 30 min to 7 days (episodic) 4–72 h 15–180 min 2–30 min Continuous headache 1–600 s 1–120 s
Frequency Episodic or chronic (variable
from rare to daily)
Episodic or chronic (variable
from rare to daily)
1–8/day >5 daily for more than
half of the time
Continuous headache >1 daily for more than
half of the time
Very variable
frequency
Pain type
Location Bilateral Unilateral or bilateral Unilateral Unilateral Unilateral Unilateral; V1/V2>V3 Unilateral; V2/V3>V1
Quality Pressing/tightening
(non-throbbing)
Throbbing Variable Variable Variable Neuralgiform pain Neuralgiform pain
Severity Mild to moderate Moderate to severe Very severe Very severe Moderate to very
severe
Very severe Very severe
Migrainous
symptoms
– +++ +/– – +/– – –
Autonomic features No +/– +++ +++ +++ +++ Sparse
Triggers Alcohol (within
30 min)
Cutaneous Cutaneous
Indometacin
response
+/– (as simple analgesic) ± (as simple analgesic) – +++ +++ – –
Based on framework of International Headache Society Classification Criteria.
Chronic migraine is defined as headache occurring on 15 or more days per month for more than 3 months, which has the features of migraine headache on at least 8 days per month. Chronic cluster headache and
paroxysmal hemicrania are defined as headache attacks occurring for more than 1 year without remission or with remission periods lasting less than 1 month.
SUNA, short-lasting unilateral neuralgiform headache with cranial autonomic symptoms; SUNCT, short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing.
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These include diencephalic and brainstem nuclei that
can modulate the perception of activation of the trige-
minovascular system, which carries sensory informa-
tion from the cranial vasculature to the brain.
Moreover, the involvement of a multisensory disturb-
ance that includes light, sound and smell, as well as
nausea, suggests the problem may more broadly
involve central modulation of afferent traffic. Brain
imaging studies in migraine suggest that subcortical
structures are important causing migraine. Thus, it
may be considered an inherited dysfunction of
sensory modulatory networks with the dominant dis-
turbance affecting abnormal processing of essentially
normal neural traffic.
Diagnosis and assessment
The first step is the accurate and positive diagnosis of
migraine; this is usually straightforward. To select the
most appropriate management, the migraine pheno-
type needs to be categorised as either episodic (occur-
ring on fewer than 15 days a month) or chronic
(occurring on more than 15 days a month, for over
3 months and with migrainous headaches on at least
8 days a month). The clinician should scrutinise the
history for sinister features. If there is a strictly unilat-
eral headache, consider hemicrania continua and
conduct an indometacin challenge. Look out for
medication-overuse headache, as this frequently coex-
ists with migraine.
We frequently use a headache diary to quantify the
headache and to provide a contemporary record of
pain, as otherwise this can suffer from recall bias. The
diaries also assist when monitoring the treatment
response, identifying triggers, the relationship to
menses and the frequency of analgesic use.
Questionnaires can help to determine the degree of
disability at baseline and to evaluate the response to
treatment (such as the Headache Impact Test (HIT 6),
the Migraine Disabilities Assessment Test (MIDAS)).
The Hospital Anxiety and Depression Scale (HADS)
can also help to assess the emotional and psychiatric
comorbidity. This is particularly important in these
patients and may influence the decision on preventa-
tive therapy, since many of these can exacerbate
depression and anxiety.
Non-pharmacological management of migraine
Although an enquiry about migraine triggers is useful,
in reality certain triggers cannot be avoided (eg, lack
of sleep, too much sleep, stress, heat). It may also be
difficult to distinguish a true migraine trigger from
premonitory symptoms occurring in the period before
an attack (food cravings, fatigue, irritability).
Patients who seek a therapeutic intervention yet are
reluctant to use medication have several options.
Neurostimulation is one possibility and we shall cover
this in the linked article. The UK’s National Institute of
Health and Care Excellence (NICE guideline CG 150)
also advocates acupuncture an alternative second-line
therapy for migraine. Although there are limited data
to support its use in migraines, it is safe, and many
patients have at least considered this before attending
the clinic. A large study comparing acupuncture with a
sham procedure and with standard migraine prophy-
lactics found no significant difference between treat-
ment groups in the number of migraine days, although
all interventions were effective.6 Furthermore, acu-
puncture appears to improve health-related quality of
life for many chronic migraineurs at relatively low
cost.7 In many hospitals, the physiotherapy department
offers an acupuncture service, but patients can also
access it from primary care.
Cognitive behavioural therapy with a trained clinical
psychologist may help, particularly combined with
medication, but there is very limited evidence of effi-
cacy. Many patients understandably have negative
thoughts and emotions linked to the headache pain.
Cognitive behavioural therapy can help to explore
these and potentially lessen this burden, thereby also
reducing anxiety.
Acute management of migraine
Practice has gradually shifted from a treatment para-
digm involving gradually escalating abortive therapy
towards now starting with combination therapy—non-
steroidal anti-inflammatory drugs (NSAIDs) or para-
cetamol and triptan—from the outset (box 1).8 This
shift follows the NICE (CG150) guideline’s cost–
utility analysis, which evaluated costs and Quality-
Adjusted Life Years (QALY) outcome measures. Based
on this analysis, triptan plus NSAIDs combination was
Box 1 Acute management of migraine
Acute migraine management
National Institute of Health and Care Excellence (NICE)
guidelines
1. Combination therapy: triptan+non-steroidal anti-
inflammatory drug (NSAID) or paracetamol+antiemetic
2. Alternatively (per patient request):
▸ a single agent (triptan, NSAID or paracetamol)
±antiemetic
NSAID
▸ Aspirin 600–900 mg (ideally effervescent)
▸ Ibuprofen 600–800 mg
▸ Naproxen 500–1000 mg
▸ Diclofenac 50–75 mg (or 100 mg suppository)
▸ Tolfenamic acid 200 mg
Antiemetics
For nausea and/or as a prokinetics such as
▸ Domperidone 10 mg up to three times a day
(or 60 mg suppository)
▸ Metoclopramide 10 mg
▸ Prochlorperazine 3–6 mg as buccal preparation
REVIEW
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more effective than other acute migraine approaches,
including triptan monotherapy (box 1 shows costs for
various triptans); this, therefore, offers patients the
best hope of rapid migraine resolution for an acute
attack.9 The guideline’s recommendation includes an
antiemetic, even if nausea is not pronounced, to
counter gastric stasis and so facilitating tablet absorp-
tion and pain relief. Last year, the European Medicines
Agency issued a warning about domperidone being
associated with a small risk of sudden cardiac death
and fatal arrhythmias, particularly in those aged over
60 years. They recommended avoiding its prolonged
use or doses above 30 mg daily. Patients taking medica-
tions that prolong the electrocardiography Q wave to
Twave interval should avoid it and those with cardiac
comorbidities should exercise caution. NICE recom-
mends avoiding ergots and opioids.
The triptans
We advise patients to use a triptan at the start of the
headache phase of a migraine attack, since there is no
evidence of efficacy if taken during preceding aura.10
Using a triptan at the start of the headache may reduce
headache recurrence, prevent disability and possibly
reduce central sensitisation. The difficulty arises in
chronic migraineurs, since taking the triptan early can
lead to a pattern of increasing use and medication-
overuse headache. We try to help these people to iden-
tify early features that might indicate an ensuing severe
migraine attack, as the triptan should be reserved for
these headaches. It is important to explain that the
triptan should be used, on average, on no more than
2 days per week (10 days per month) to reduce the risk
of a triptan-overuse headache.
Our own practice is to try any particular triptan on
at least three occasions before assessing its efficacy.
Poor efficacy or tolerability with a single triptan does
not reliably predict response to another, so it is defin-
itely worthwhile working through different agents.
However, choosing the right triptan for a given situ-
ation can be difficult, especially when considering
second-line or third-line choices. Figure 1 and the fol-
lowing section may assist this decision.
Which triptan and how do they work?
The seven triptans—almotriptan, eletriptan, frovatrip-
tan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
—are 5HT1B/1D receptor agonists with vasoconstrict-
ive effects on blood vessels. The choice of triptan
depends on efficacy, side effects, the duration of the
headache, coexisting vomiting and cost (table 2).
Efficacy of triptans
Efficacy data at 2 h favour eletriptan, then rizatriptan,
followed by zolmitriptan over sumatriptan, almotrip-
tan, naratriptan, and frovatriptan. At 24 h, eletriptan
performed best, followed by zolmitriptan and then
almotriptan, rizatriptan and sumatriptan (100 mg).11
However, the most effective use of a triptan
depends partly upon its route of administration. Thus,
the most effective sumatriptan preparation for acute
Figure 1 Triptan selection in acute migraine. An approach to triptan selection based on the characteristic of acute attacks.
BD, twice daily; NSAID, non-steroidal anti-inflammatory drug; TDS, three times a day.
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relief at 2 h (based on numbers needed to treat) was
subcutaneous 6 mg, then intranasal 20 mg and then
oral 100 mg formulations.12 While subcutaneous
sumatriptan is most effective, it has more adverse
events and costs more than triptans by other routes.
The route of administration of the triptan is therefore
best tailored to the individual’s migraine attack. For
example, if the migraine has a rapid onset, patients
may try a fast-acting oral triptan such as rizatriptan,
zolmitriptan or eletriptan, or nasal preparations that
are faster still (zolmitriptan and sumatriptan); alterna-
tively, the subcutaneous sumatriptan, which has the
fastest onset of action. Other migraine features neces-
sitate specific strategies (as outlined in figure 1).
Safety and side effects
We find the triptans to be well tolerated overall. The
reported incidence of minor adverse effects does not
differ markedly between the triptans, but depends on
speed of onset of action; people taking subcutaneous
sumatriptan report more adverse effects than those
taking oral sumatriptan. The triptans with a longer
half-life and slower onset of action, such as naratrip-
tan and frovatriptan, have fewer side effects. The
adverse effects of the oral triptans are similar,
although dizziness and sedation occur more with riza-
triptan and zolmitriptan than with sumatriptan and
naratriptan.13
There are cardiovascular safety concerns associated
with triptan use due to the presence of 5HT1B recep-
tors on vascular smooth muscle. We avoid triptans in
people with uncontrolled hypertension, cardiovascular
and/or cerebrovascular disease. However, in clinical
trials, cardiovascular complications were fewer than
one per million exposed, and a recent systematic
review of cardiovascular safety data identified no
strong cardiovascular safety issues.14 Triptan sensa-
tions such as burning or tingling in the chest or limbs
are relatively common (7%), but clinicians can
reassure patients that this is not associated with
cardiac ischaemia.15
In 2006, the US Food and Drug Administration
(FDA) identified the potential for developing a sero-
tonin syndrome when taking triptans together with
selective serotonin reuptake inhibitors (SSRIs) and
serotonin/norepinephrine reuptake inhibitors
(SNRIs).16 However, on further evaluation only 10 of
the original 36 cases identified were actually serotonin
syndrome and it was concluded that triptan use did
not need to be restricted in patients on SSRIs or
SNRIs.17 We use triptans in these patients where indi-
cated but counsel patients to be aware of the features
of serotonin syndrome (agitation, nausea, palpitation
and sweating). Triptans should not be co-prescribed
with ergotamine (within 24 h) or monoamine oxidase
inhibitors (within 2 weeks).
Triptans in pregnancy and breast feeding?
The major concern for migraine medications during
pregnancy is of potential teratogenicity; our practice
during pregnancy is to continue triptans only if
benefit outweighs risk. The sumatriptan pregnancy
register (626 pregnancies exposed to sumatriptan) has
highlighted that the risk of first trimester birth defects
was 4.2%, versus 3–5% in the general population.18
There are fewer data for other triptans. The current
NICE CG150 headache guideline states that triptans
can and should be considered for pregnant patients
experiencing disabling headache attacks when other
therapies have proven unhelpful and when patients
have been counselled about their use in pregnancy.
Triptans are generally considered compatible with
breast feeding as less than 10% of the drug dose
appears in breast milk; however, there are no large
studies in this area.
Should we use triptans in patients with migraine aura?
Auras were previously thought to represent a vasocon-
strictive episode and consequently there was concern
about using triptans, which cause vasoconstriction, as
this might in theory predispose to stroke. However,
current understanding is that cortical spreading
Table 2 The triptans
Triptan Peak serum concentration Half-life Usual dose (maximum daily dose) Cost (per tablet)
Almotriptan 1.5–2 h 3.5 h 12.5 mg (25 mg) 3.0 GBP (12.5 mg)
Eletriptan 1.5–2 h 4 h 40 mg (80 mg) 3.8 GBP (40 mg)
Frovatriptan 2–4 h 26 h 2.5 mg (5 mg) 2.8 GBP (2.5 mg)
Naratriptan 2–3 h 6 h 2.5 mg (5 mg) 3.8 GBP (2.5 mg)
Rizatriptan 1–1.5 h 2 h 10 mg (20 mg)—same recommendation
for rizatriptan melt
4.5 GBP (5 mg)
Sumatriptan 2–3 h 2 h 50–100 mg (300 mg) 0.3 GBP (50 mg)
Sumatriptan subcutaneous 12 min 1.9 h 6 mg (12 mg) 21.2 GBP (per injection)
Sumatriptan intranasal 1–1.5 h 2 h 10–20 mg (40 mg) 5.9 GBP (per dose)
Zolmitriptan 1–1.5 h 2.5 h 2.5–5 mg (10 mg) 3.8 GBP (2.5 mg)
Zolmitriptan intranasal 15 min 3 h 5 mg into one nostril, once (10 mg) 11.0 GBP (per spray)
Drugs listed alphabetically. All doses apply to the oral route, except where otherwise specified.
GBP, pounds sterling.
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depression underlies aura, calling into question this
theoretical contraindication.19 Studies of triptan use
in familial hemiplegic aura report an excellent
response to triptans and only minor side effects.20
Opinions vary among headache physicians, depending
on the type of aura. Triptans are generally prescribed
for migraine associated with non-motor aura.
However, for hemiplegic migraine and also basilar
migraine, there is less consensus, but the potential
benefit of triptans may well outweigh their theoretical
risks.
Migraine prevention
Migraine preventative treatments aim to reduce the
frequency and severity of attacks and may help reduce
the frequency of analgesic use. It is usually unrealistic
for patients to expect complete headache cessation
and it can be useful to have a discussion with patients
about realistic goals of treatment. Prophylactic treat-
ment is typically considered if there are more than
four migraine days per month. However, preventative
therapy may also be given for less frequent but very
disabling attacks.
Most medications used as preventatives were originally
used for a different indication, and the evidence for indi-
vidual agents varies. The agents used can be classified
into antiepileptic drugs, beta blockers, antidepressants,
serotonergic antagonists (methysergide is no longer man-
ufactured), calcium channel antagonists, angiotensin
modulators (ACE inhibitors and angiotensin-receptor
inhibitors), nutrients and herbal products (Feverfew).
The current NICE guideline suggests first trying
either topiramate or a beta blocker. If both are inef-
fective or contraindicated, then consider acupuncture,
gabapentin, botulinum toxin or riboflavin.8 Since the
publication of this guideline, there is new evidence
that gabapentin is not effective, so we no longer use
this.21 22 The NICE guideline also concluded that
there was insufficient evidence to support using ami-
triptyline and pizotifen, due to lack of robust clinical
trials in this area.8 In reality, the choice of preventative
depends in part on NICE guidelines, but is also influ-
enced by patient comorbidities; thus, we also consider
other agents as outlined in table 3.
It is important to note that topiramate, flunarizine
and beta blockers can exacerbate depression. Weight
gain can be a concern with beta blockers, pizotifen,
flunarizine, valproate and antidepressants. Beta block-
ers cannot be used in people with asthma (candesartan
is a useful alternative with equivalent efficacy to pro-
pranolol). The tricyclic antidepressants, particularly
amitriptyline, can be sedating though this can make it
the drug of choice in people with sleeping difficulty.
Topiramate can reduce the efficacy of the contracep-
tive pill. Also, many agents are potentially teratogenic
and this should be mentioned to women of childbear-
ing age.
The general rules of thumb are to start treatment at
a low dose, gradually increasing to an initial target
dose. If there is no effect and no significant side
effects, the dose can be further increased for some
drugs. We continue the medication for at least
3 months to evaluate efficacy. If effective (about a
50% improvement) the drug may be continued for
6 months, although there is some evidence of fewer
rebound headaches if continued for 12 months.23
There is very limited evidence to support the use of
SNRIs in migraine.
Botulinum toxin for migraine
If three or more migraine preventatives have been
trialled at effective dosages, the NICE guideline
recommends doctors to consider botulinum toxin
type A in chronic migraineurs (more than 15 head-
ache days per month of which at last 8 are migrain-
ous, for more than 3 months), provided there has
been adequate management of medication overuse.
Botulinum toxin therapy should be stopped if it
fails to provide the required response (a less than 30%
reduction in headache days per month after two
cycles), or if the headache has returned to an episodic
phenotype.10 Earlier this year, longitudinal data from
one of the largest botulinum toxin-treated migraine
cohorts (refractory to preventative medications)
demonstrated significantly more pain-free days and
improved quality of life.24
Pregnancy and migraine
Around 70% of migraineurs improve during preg-
nancy (especially second and third trimesters). If
migraines are troublesome during the pregnancy, the
choice of abortives should be discussed (see The trip-
tans section). NSAIDs can be used in early pregnancy,
but are absolutely contraindicated in the third trimes-
ter. Aspirin is a particular concern due to the possibil-
ity of developing Reye’s syndrome in the neonate. Of
the abortives, paracetamol is probably the safest.
During pregnancy, we tend to review patients with
severe migraine more frequently to monitor progress
and to discuss treatment options. There are under-
standably few data on which agents are safe in preg-
nancy and most drugs are unlicensed for use in
pregnancy. Preventatives should be prescribed only if
the potential benefits outweigh the potential risks.
Low-dose (10–50 mg) amitriptyline is sometimes pre-
scribed; however, there are reports of limb deformities
following prenatal exposure to higher doses. Beta
blockers may increase the risk of intrauterine growth
retardation (25% risk with atenolol). Sodium valpro-
ate should be avoided. There is an excellent review of
this topic available.25 Greater occipital nerve (GON)
blocks may provide short to medium term analgesia.
External neuromodulation using a single-pulse tran-
scranial magnetic stimulation device was recently
shown to be both safe and effective.26
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Table 3 Migraine preventatives: an overview
Drug class Drug Side effects & contraindications Target dose Regimen
Beta blocker Propranolol (alternatively
atenolol or metoprolol)
Fatigue, depression, weight gain, bradycardia, impotence, orthostasis. Avoided in COPD/asthma,
diabetes mellitus, peripheral vascular disease and those with bradyarrhythmias
80 mg BD (Atenolol 50–200 mg
per day)
(Metoprolol 100–200 mg per day)
Start 40 mg bd, titrate up to
160–320 mg daily
Serotonin
antagonist
Pizotifen Drowsiness, weight gain, dry mouth, urinary retention and manufacturers suggest avoiding in
people with glaucoma, urinary retention, renal dysfunction and epilepsy
3 mg daily Start at 0.5 mg OD, increase
by 0.5 mg every 1–2 weeks
Antidepressant Tricyclic
Amitriptyline (alternatively
dosulepin or nortriptyline)
Sedation, weight gain, dry mouth. Avoid amitriptyline in people with glaucoma, urinary retention,
hypotension and significant cardiovascular comorbidity, including arrhythmias. Use with caution in
people with epilepsy
50–75 mg daily Start 10 mg ON with 10 mg
⇑ every 1–2 weeks
SNRI
Duloxetine (alternatively
venlafaxine)
Constipation and diarrhoea, weight gain. Avoid in uncontrolled hypertension 60–90 mg Start 30 mg, increase every
week by 30 mg
Antiepileptic Topiramate Topiramate may have cognitive, anxiety and depression-provoking effects and may promote weight
loss. Rarely renal calculi and glaucoma. Topiramate induces the metabolism of the combined
contraceptive pill
100 mg Start at 25 mg, ⇑25–50 mg
every 1–2 weeks
Valproate Valproate can cause weight gain, tremor, alopecia and haematological dyscrasias. It can cause
hyperammonaemia and is teratogenic. It should be avoided in liver disease (potentially hepatotoxic)
1000 mg Start at 200 mg OD, ⇑
200 mg every 2 weeks
Angiotensin based Lisinopril Lisinopril may cause fatigue, dry cough, angioedema, orthostasis or confusion. Hyperkalaemia or
bone marrow dysfunction should be avoided
20–40 mg OD Start at 10 mg OD,
⇑ to 20–40 mg
Candesartan Candesartan can cause vertigo and hypotension. It should therefore be avoided in individuals with
these disorders
8 mg BD Start 4 mg OD, titrate by
4 mg every week
Calcium channel
blocker
Flunarizine Weight gain, depression and extrapyramidal effects. May cause galactorrhoea in women
concomitantly taking the combined contraceptive pill
5–10 mg 5 mg for a month, then
10 mg
Neutriceutical Magnesium In hypermagnesaemia, gastrointestinal (GI) effects, arrhythmia and coma are reported 600 mg daily –
Riboflavin Physiologically limited absorption, limiting adverse effects 400 mg –
CoQ10 CoQ10 can cause usually mild GI effects, such as upset stomach 100 mg TDS –
BD, twice daily; COPD, chronic obstructive pulmonary disease; OD, once daily; ON, once nightly; SNRI, serotonin norepinephrine reuptake inhibitor; TDS, three times a daily.
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Menstrual migraine
Menstrual migraines have been attributed to falling
oestrogen levels premenstrually and perimenstrually.
‘Perimenstrual mini’ prophylaxis (starting 2 days
before the period and continuing during the period)
can help, for example, frovatriptan 2.5 mg twice daily,
zolmitriptan 2.5 mg three times a day, naproxen
500 mg twice daily or mefenamic acid 500 mg three
times a day. Contraceptive-induced amenorrhoea can
also be very effective, for example, with tricycling or
continuous combined contraceptive pill.27 Oestrogen
gels or patches can ameliorate the effect of falling
serum hormone concentrations before and during the
period (eg, 1.5 mg transcutaneous oestrogen days −2
to +5).
GON block for migraine
Neurologists working in the headache field, especially
in the USA and latterly the UK, have used GON local
anaesthetic blocks; these can provide analgesia for up
to 2 months in chronic migraine sufferers. A recent
double-blind randomised controlled trial of low-dose
local anaesthetic block versus high-dose local anaes-
thetic block, however, challenged this notion of its
sustained efficacy.28 A GON local anaesthetic block
can provide a short-term rescue intervention for a
patient in crisis. We sometimes use GON blocks to
provide analgesia when starting prophylactic treat-
ment in disabling refractory status migrainosus, to
facilitate withdrawal of acute analgesics in those with
medication-overuse headache and for patients with
troublesome migraine in pregnancy. The exact com-
position of the nerve block can vary between centres.
We tend to use 80 mg depomedrone (40 mg/mL) and
2 mL of 2% lignocaine, that is, total 4 mL per injec-
tion into each GON (figure 2). Some centres
substitute the lignocaine for 1 mL of 0.5% bupiva-
caine. The efficacy and use of GON blockade in
primary headache other than migraine, for example,
cluster headache, is already better established.
Migraine and the combined contraceptive pill?
Women with migraine and active aura have a twofold
increased risk of ischaemic stroke.29 In women aged
less than 45 years, smoking and the combined contra-
ceptive pill further increase the stroke risk.30 NICE
recommends avoiding combined hormonal contracep-
tives in women who have migraine with aura due to
the increased risk of stroke. In these patients, we rec-
ommend the progesterone-only pill, contraceptive
implant, depot or levonorgesterol intrauterine device.
Treating headache in the emergency department
When managing acute, severe headache in the emer-
gency department, our first concern is to identify red
flags (see table 4). An accurate headache history is
essential and if a true thunderclap or sinister headache
is identified this will need investigating.
When there is a positive diagnosis of severe
migraine, its effective management can ensure high-
quality patient care and also facilitates a timely dis-
charge. We offer sumatriptan 6 mg, typically with an
antiemetic such as metoclopramide or prochlorpera-
zine. A recent systematic review advised against using
morphine, tramadol, intramuscular diclofenac, halo-
peridol or dexamethasone.31 A period of intravenous
rehydration may also help. It is also essential to make
a future management plan to help prevent readmis-
sions, which often are multiple in severe migraineurs.
Clinicians can review the need for migraine prophy-
laxis and abortive therapy as an outpatient. A GON
block can help patients in crisis before discharge.
Figure 2 Injection sites for greater occipital nerve (GON) block. The injection sites (A and B; one to each GON) are identified as
being at the proximal third of the distance between a hypothetical line from the occipital protruberance to the mastoid process. GON
block side effects include a local alopecia, transient dizziness and worsening of the headache. The block can be repeated about every
3 months.
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MEDICATION-OVERUSE HEADACHE
Medication-overuse headache is headache occurring
on 15 or more days per month, developing as a conse-
quence of regular overuse of acute or symptomatic
headache medication (simple analgesics and NSAIDs
on 15 days or more; or triptans, opioids and combin-
ation analgesics on 10 days or more days per month)
for over 3 months. It occurs in patients with pre-
existing primary headache who, in association with
regular acute medication use, develop a new type of
headache or a marked worsening of their pre-existing
headache. Phenotypically, the headaches usually
resemble migraine or tension-type headache.
Medication-overuse headache is a common, fre-
quently debilitating, sequel to pre-existing headache.
Headaches develop on withdrawal of analgesics, trig-
gering more analgesic usage, leading to a self-
perpetuating cycle. The problem is more severe with
overuse of triptans and opiates than, for example,
NSAIDs and simple analgesics, but can develop fol-
lowing overuse of any analgesic. A detailed look at a
patient’s list of over-the-counter medication can be
quite revealing (table 5).
Unfortunately, the process of withdrawing from
analgesics is often challenging. Patients may develop
not only a withdrawal or rebound headache but also
nausea and other gastrointestinal disturbances (about
a week for triptan withdrawal and up to 4 weeks for
opiates and codeine-based medication). Before with-
drawal, it is important that the patient is fully aware
of the likely initial worsening of symptoms.
The overused abortives should ideally be stopped for
at least 1 month. It can be encouraging to the patient
to explain the evidence that medication withdrawal
alone can improve the headaches (see figure 3).
How do we manage medication-overuse headache?
The aims of medication withdrawal are to reduce the
headache frequency and severity and to optimise the
efficacy of migraine preventatives. There is contro-
versy as to whether migraine preventatives should be
started while there is still ongoing medication overuse.
Most patients can withdraw their analgesics as an
outpatient. They can opt either to stop the analgesics
abruptly or alternatively to wean down by increasing,
Table 4 Secondary headaches presenting to the emergency department
Cause Clinical features
Vascular
Subarachnoid haemorrhage Nuchal rigidity, thunderclap headache, altered consciousness, nausea/vomiting, possibly focal neurological deficit
(vasospasm, infarction)
Arterial dissection (carotid or
vertebral artery)
Neck pain, focal neurological deficit if associated stroke
Venous sinus thrombosis Headache (can be thunderclap), visual obscurations, papilloedema, focal signs, seizures. Increased risk with the
combined contraceptive pill or other prothrombotic risk factors (eg, pregnancy)
Infective
Meningitis Fever/septic features, nuchal rigidity, nausea/vomiting, altered awareness, rash, photophobia
Encephalitis As above, but also focal neurological deficit, confusion, seizures
Sinusitis/mastoiditis Fever/septic features, sinus tenderness, altered hearing, nasal or aural discharge
Abscess Fever/septic features, focal neurological signs, altered awareness, papilloedema
Ophthalmological
Acute angle-closure glaucoma Red eye, large oval pupil, unilateral visual disturbance
Inflammatory
Giant cell arteritis Age >50 years, unilateral visual loss, general malaise, weight loss, scalp tenderness, jaw claudication, raised
erythrocyte sedimentation rate/serum C reactive protein)
Altered cerebrospinal fluid dynamics
Idiopathic intracranial hypertension Typically young women with high body mass index, visual obscurations/blurring, papilloedema and tinnitus
Colloid cyst of the third ventricle Headache, gait disturbance, drop attacks
Low-pressure headache Headache improved lying down, may be exacerbated by the valsalva manoeuvre
Space-occupying lesion with pressure
effects
Headache (new, worsening, change in phenotype) may have associated lateralising features or seizure
Table 5 Common over-the-counter migraine acute treatments
Symptomatic treatment Contents
Anadin Paracetamol
Anadin extra aspirin, paracetamol and caffeine
Hedex extra paracetamol and caffeine
Migraleve paracetamol, codeine and buclizine
Panadol advance and actifast Paracetamol
Panadol extra paracetamol and caffeine
Panadol ultra paracetamol and codeine
Paracodol paracetamol and codeine
Paramol paracetamol and dihydrocodeine
Solpadeine ibuprofen and codeine
Solpadeine headache paracetamol and caffeine
Solpadeine max paracetamol, codeine, caffeine
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by 1 day each week, the number of medication-free
days. Opiates and codeine-based medication may need
to be gradually reduced, as the withdrawal symptoms
can be severe. There is only sparse evidence support-
ing the use of alternative acute treatments during
withdrawal. Naproxen 500 mg twice daily during the
withdrawal can help as a short-term measure. We
sometimes offer GON blocks to tide the patient
through a period of drug withdrawal.
Some patients may need inpatient withdrawal, par-
ticularly those who also have substance abuse, additional
unrelated medical morbidities or multiple high-dose
analgesic overuse. Inpatient regimens may include intra-
venous hydration, dexamethasone, intravenous antie-
metics and occasionally benzodiazepines or
chlorpromazine. Some centres have access to and use
intravenous aspirin (lysine acetylsalicylate) and/or intra-
venous dihydroergotamine with significant benefit.32
TENSION-TYPE HEADACHE
Tension-type headache accounts for 45–80% of head-
ache diagnoses in the general population. It is gener-
ally less severe than migraine, and patients may seek
only reassurance. Many can manage with simple anal-
gesia. People with chronic tension-type headache can
use preventative treatments, for example, amitriptyline
or topiramate.33 There is also evidence for non-
pharmacological approaches, including acupuncture.8
CLUSTER HEADACHE
Cluster headache is the most common of the trigem-
inal autonomic cephalalgias. Patients experience
excruciating unilateral pain lasting 15–180 min at an
attack frequency of 1–8 per day, usually at predictable
times. The attacks occur in bouts of weeks to months
and may repeat multiple times in a year with circann-
ual periodicity. Pain is typically in an orbital, supra-
orbital and temporal distribution with associated
autonomic features and agitation. Around 80% of
cluster is episodic but in about 1 in 10 becomes
chronic—headache attacks occurring for over
12 months without remission or with remission
periods of less than 1 month.
Management of cluster headache
Treatment strategies are either abortive (acute pain
relief ), transitional or prophylactic. The first-line
abortive strategy is subcutaneous sumatriptan 6 mg
(maximum two per day), with most people obtaining
pain relief within 15 min (effective in 75%). If this
cannot be used or tolerated, intranasal sumatriptan
20 mg or zolmitriptan 5 mg are alternatives but can
take up to 30 min for their full effect. Home oxygen
can be very useful at high flow, 100% concentration,
via a non-rebreathe mask at 12–15 L/min for up to
20 min. In the UK, this is ordered via a Home
Oxygen Order Form (HOOF-A). If carbon dioxide
retention is a concern, we initially obtain an arterial
blood gas sample and undertake formal respiratory
assessment. If it is effective, then patients can use
ambulatory oxygen to take to work and so on (in the
UK, this requires a HOOF-B). These small cylinders
contain around 30 min of oxygen, so patients need an
ample supply.
Transitional treatments can help the patient get
through a crisis period while starting preventative
strategies. Prednisolone can be used, typically at 1 mg/
kg up to 60 mg, for 5–7 days before tapering over
2 weeks. However, the efficacy rapidly diminishes
during corticosteroid withdrawal and prolonged or
multiple courses of corticosteroids carry significant
side effects. GON blocks can also be very effective in
reducing the attacks in the short term.34
Patients may need a preventative therapy to shorten
the duration of the cluster bout and to help to control
pain. Verapamil has proven efficacy in reducing the
frequency of cluster headache after the first week,
with a reduced median number of cluster headaches
per day (1.65 on placebo vs 0.6 on verapamil).35 We
perform ECG before starting verapamil, and again
with each dose increase, looking for a prolonged elec-
trocardiography P wave to R wave interval. A typical
starting dose is 240 mg with 80 mg increments.36
Some centres use a faster titration although there are
no safety studies to evaluate this regimen (see online
supplementary table S1). Second-line agents include
lithium carbonate (see online supplementary table S2)
and topiramate. There is less evidence for gabapentin,
melatonin and sodium valproate but we may occasion-
ally use these if other agents fail.
Figure 3 Headache frequency after medication withdrawal in
medication-overuse headache. This Danish study of people with
probable medication-overuse headache (175 patients) compared
the frequency of headache before and after complete drug
withdrawal and then after drug management in the clinic.
Between the initial visit (before withdrawal) and discharge from
clinic post-withdrawal, there was a mean reduction in headache
frequency across the cohort of 46% (p<0.0001). The values
represent mean reduction in headache days per month with
median and range in brackets. *p<0.0001 (adapted from
Zeeburg et al44).
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Future directions for cluster headache management
There is growing evidence for using neuromodulation
(both invasive and non-invasive) in headache; this
appears a promising avenue for future treatment,
which we await with enthusiasm. Among the neuro-
modulation options, non-invasive vagus nerve stimula-
tion (GammaCore) shows promising results for cluster
headache and migraine. There have also been very
encouraging results using the invasive sphenopalatine
ganglion stimulator to reduce pain in patients with
intractable chronic cluster headache.37 We shall cover
this in more detail in a linked article.
FUTURE TREATMENTS
Future headache treatments have several key themes.
The increased scrutiny of widely used antiepileptic
drugs as possible migraine treatments, the evaluation
of new modes of triptan delivery and the use of drug
from altogether novel classes.
Calcitonin gene-related peptide (CGRP) therapy
A promising novel strategy focuses on calcitonin
gene-related peptide (CGRP). This is a potent vasodila-
tor, a trigger for migraine episodes and is raised during
migraine and cluster attacks. Early CGRP antagonist
trials started well but have been halted due to adverse
liver reactions. However, early data from CGRP anti-
body therapy trials are encouraging.38 CGRP antibodies
used as abortive agents are attractive compared with
triptans as they do not cause vasoconstriction, and so
potentially can help a larger population of patients.
New triptan formulations and delivery methods
There are several new methods to deliver triptan
therapies.
▸ The Optinose apparatus (Avanir) delivers sumatriptan
powder into the higher nasal mucosa through blowing
into the device; initial evidence suggests that this is
rapidly effective. It may soon be available in the USA.39
▸ Needle-free subcutaneous sumatriptan, delivered through
a high-pressure canister into the skin (Sumavel), may be
useful in needle-phobic patients.40
▸ The Zecuity patch (NuPathe) is an FDA-approved trans-
dermal sumatriptan patch that permits electronically
controlled delivery.
▸ A new zolmitriptan oral dispersible film (Applied
Pharma Research, Labtec, MonoSolRx) has been
approved for use in most of Europe.
▸ New serotonin agonists, such as lasmiditan, have greater
selectivity for the desired 5-HT1F receptors. These may
also have a role due to their ability to minimise risks of
significant vasospasm through unwanted binding of
other serotonin receptors. Lasmiditan was effective in
trials of acute therapy of migraine.41
Antiepileptic drugs
Antiepileptic drugs, not historically appreciated for
their benefit in managing migraine, have generated
heightened interest recently—particularly levetirace-
tam and lacosamide—with the recognition of the role
of cortical hyperexcitability in migraine development.
We need further studies to evaluate their efficacy.42
Other agents
As knowledge of the pathogenic mechanisms
involved in headache increases, new agents are devel-
oped specifically to target headache pain. Melatonin
receptor agonists, for example, ramelteon, were
developed following evidence of pineal dysfunction
in headache. Trials are currently underway in this
area (NCT00739024). Tonabersat is currently being
evaluated as a drug to inhibit spreading cortical
depression.43
CONCLUSIONS
The effective management of headache disorders
remains a moving field and a potential challenge to
the neurologist. The frequency of headache and its
burden of disability make it essential for neurologists
to manage headache in an informed way. Therapeutic
decisions are hampered by minimal evidence to
support the use of many therapies and hence we a
need large, robust clinical trials. However, emerging
therapies specifically targeting headache pain path-
ways are likely to improve significantly the manage-
ment options and advance the field.
A practical approach is important—using existing
evidence and guidelines—to enable effective headache
management. It is an area where the clinician can
have a huge and very rewarding impact upon patient
care.
Key points
▸ Headache is a common cause of disability; an accur-
ate diagnosis is essential, though is often delayed or
missed.
▸ Medication-overuse headache frequently coexists and
should be actively sought and discussed with patients
with headache.
▸ National Institute of Health and Care Excellence
(NICE) recommends acute migraine abortive treat-
ment with a triptan together with paracetamol (or a
non-steroidal anti-inflammatory drug) plus an antie-
metic; lack of efficacy with one triptan does not
mean that others will not work.
▸ NICE guidelines for migraine prophylaxis suggest
using topiramate or a beta blocker; comorbidities or
lack of efficacy often means that other agents are
also prescribed.
▸ Start migraine prophylactic agents at low dose, build
the dose up progressively and maintain a therapeutic
dose for 3 months before judging its efficacy.
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